secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001753926-24-000356
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell Therapeutics prices IPO at $6.00/share, raises $6.6M gross, lists on NYSE American
--------------------------------------------------------------------------------

- Sold 1,100,000 shares at $6.00; gross proceeds ~$6.6M; closed Feb 21, 2024.
- Effected 9:1 reverse stock split; amended charter and bylaws effective Feb 15, 2024.
- Underwriter granted 55,000-share warrant at $7.50 (125% of IPO price), exercisable from Aug 2024 to Feb 2029.
- Selling stockholders registered up to 2,969,823 shares for resale; Company receives no proceeds from those sales.
- Net proceeds earmarked for CC8464 studies, eye pain/neuropathic pain trials, Phase 2a Erythromelalgia study, spray-formulation development, and promissory note repayment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/0001753926-24-000356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/g084068_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer